Lawrence David Sher MD

Allergy & Immunology•Rolling Hills Estates, CA

Asthma & Allergic Conditions, Pediatric Asthma & Allergic Conditions

Palos Vedes Medical Group

501 Deep Valley DrSuite 210Rolling Hills Estates, CA 90274
Phone+1 310-544-6858
Fax+1 310-544-6855

Dr. Sher is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sher's full profile Already have an account?

Summary

Dr. Lawrence Sher is an allergist and immunologist based in Rolling Hills Estates, CA, specializing in asthma and allergic conditions, with a focus on pediatric asthma and allergies. He completed his fellowship and residency at UCLA David Geffen School of Medicine/UCLA Medical Center and graduated from the University of Utah School of Medicine in 1983. His experience includes work on pneumonia, and he has published research in several high-profile journals on topics like dupilumab efficacy and SARS-CoV-2 vaccines. Dr. Sher has also been involved in clinical trials related to asthma, egg allergy immunotherapy, and influenza. He is recognized as a Fellow by the American Academy of Allergy Asthma and Immunology.
Dr Sher currently is serving as Associate Medical Director of Headlands Research Network, 24 clinical research sites involved in multi therapeutic research trials.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Allergy and Immunology, 1986 - 1989
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1983 - 1986
University of Utah School of MedicineClass of 1983

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MI State Medical License 2026 - 2029
CA State Medical License 1984 - 2027
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification IMS, MedPharm Services LLC, 2013-2017
CMS Meaningful Use Stage 1 Certification IMS, MedPharm Services LLC, 2013-2017
Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology

Clinical Trials

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
COMPLETED
PHASE3
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome
COMPLETED
PHASE3
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
COMPLETED
PHASE3

Publications & Presentations

PubMed

1 citations
A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial.
Temitope Oyedele, Rachel Park, Kelly Morales, Manish Jain, Lawrence Sher
Vaccine. 2026-03-19
4 citations
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).
Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, Dareen Siri, Roxanne C Oriel
The Journal of Allergy and Clinical Immunology. in Practice. 2025-05-01
2 citations
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities.
Mark Boguniewicz, Lawrence D Sher, Amy S Paller, Peter D Arkwright, Shigemi Yoshihara
Advances in Therapy. 2024-12-01

Press Mentions

OCS-Sparing Effect of Dupilumab for Severe Asthma MaintainedJuly 23rd, 2022
Pandemic-Weary LA County Crestfallen over News of Masks’ Return, Mere Weeks After Restrictions EasedJuly 15th, 2021
Are We Declaring Pandemic over Too Fast? California’s June 15 Deadline for Reopening Splits ExpertsApril 8th, 2021